Synthetic Blood International, Inc. Release: Oxycyte(R) Treatment for Traumatic Brain Injury Featured in Miami Herald Article

18 Mar 2008

·www.biospace.com

COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) lead product Oxycyte® is the subject of an article in today’s Miami Herald. The article appears in the paper’s health section under the headline: “Artificial blood goes from science fiction to science fact.” Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.

Organizations

Tenax Therapeutics, Inc.

Indications

Brain Injuries, Traumatic

Targets

Drugs

Perfluorocarbon oxygen carrier

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.